PAK1 and chronic myelogenous leukemia, BCR-ABL1 positive: We found that IPA-3, a small molecule inhibitor of PAK1, can modulate the response of leukemic cancer cells to IM, a first-generation TKI and the gold standard in the treatment of patients with newly diagnosed CML-CP.